Acurx Pharmaceuticals (NASDAQ:ACXP) Announces Quarterly Earnings Results

Acurx Pharmaceuticals (NASDAQ:ACXP) announced its quarterly earnings results on Thursday. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.11), FiscalAI reports.

Acurx Pharmaceuticals Price Performance

NASDAQ:ACXP traded down $0.06 during trading hours on Thursday, reaching $1.48. 261,254 shares of the company traded hands, compared to its average volume of 1,311,702. The firm’s 50-day moving average is $1.53 and its 200-day moving average is $2.22. The stock has a market cap of $6.36 million, a P/E ratio of -0.37 and a beta of -2.03. Acurx Pharmaceuticals has a 1-year low of $1.33 and a 1-year high of $8.34.

Analysts Set New Price Targets

Several equities research analysts recently commented on ACXP shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research report on Friday, July 17th. Wall Street Zen upgraded shares of Acurx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Acurx Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $31.00.

Hedge Funds Weigh In On Acurx Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC acquired a new stake in shares of Acurx Pharmaceuticals during the fourth quarter valued at $27,000. Geode Capital Management LLC acquired a new position in Acurx Pharmaceuticals in the 4th quarter valued at about $31,000. Millennium Management LLC purchased a new position in Acurx Pharmaceuticals in the 4th quarter valued at about $103,000. Finally, Armistice Capital LLC purchased a new position in Acurx Pharmaceuticals in the 2nd quarter valued at about $551,000. 11.53% of the stock is owned by institutional investors and hedge funds.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).